Cargando…

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies

BACKGROUND: Long-acting muscarinic antagonists (LAMAs) are recommended for the treatment of chronic obstructive pulmonary disease (COPD). Glycopyrrolate/eFlow® is an investigational drug–device combination of the LAMA glycopyrrolate administered by an eFlow® Closed System (eFlow® CS) nebulizer. The...

Descripción completa

Detalles Bibliográficos
Autores principales:	Donohue, James F., Goodin, Thomas, Tosiello, Robert, Wheeler, Alistair
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715551/ https://www.ncbi.nlm.nih.gov/pubmed/29202767 http://dx.doi.org/10.1186/s12931-017-0681-z

Ejemplares similares

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
por: Ohar, Jill, et al.
Publicado: (2018)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
por: Donohue, James F, et al.
Publicado: (2020)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS
por: Stephenson, Judith J, et al.
Publicado: (2020)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
por: Siler, Thomas M., et al.
Publicado: (2021)

Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies
por: Hanania, Nicola A, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease
por: Leaker, Brian R, et al.
Publicado: (2015)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies [Corrigendum]
Publicado: (2020)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Efficacy of Glycopyrrolate in Primary Hyperhidrosis Patients
por: Lee, Hyun Ho, et al.
Publicado: (2012)

Glycopyrrolate in toxic exposure to ammonia gas
por: Bhalla, A, et al.
Publicado: (2011)

Glycopyrrolate-Induced Black Hairy Tongue
por: Prabha, Neel, et al.
Publicado: (2020)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

Iontophoretic and Microneedle Mediated Transdermal Delivery of Glycopyrrolate
por: Gujjar, Meera, et al.
Publicado: (2014)

Glycopyrrolate-induced polyuria: An unexpected side effect
por: Behera, Sunil Kumar, et al.
Publicado: (2023)

Evaluation of Efficacy and Safety of Low Dose Glycopyrrolate in Management of Primary Hyperhidrosis---An Open Label Single Arm Study
por: Vyas, Kapil, et al.
Publicado: (2020)

Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies
por: Martinez, Fernando J, et al.
Publicado: (2020)

Effectiveness of Oral Glycopyrrolate Use in Compensatory Hyperhidrosis Patients
por: Gong, Tai Kyung, et al.
Publicado: (2013)

Impact of Sugammadex Versus Neostigmine/Glycopyrrolate on Perioperative Efficiency
por: Deyhim, Niaz, et al.
Publicado: (2020)

A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease
por: Usmani, Omar, et al.
Publicado: (2021)

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Escalation Phase 1 Study of Aerosolized Pirfenidone Delivered via the PARI Investigational eFlow Nebulizer in Volunteers and Patients with Idiopathic Pulmonary Fibrosis
por: Khoo, Jun Keng, et al.
Publicado: (2020)

Comparative Study on the effectiveness of Glycopyrrolate/Formoterol versus Tiotropium/Formoterol in patients with Chronic Obstructive Pulmonary Disease
por: Jayanthi, Nalini, et al.
Publicado: (2022)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

A case report: Glycopyrrolate for treatment of exercise-induced hyperhidrosis
por: Negaard, Matthew, et al.
Publicado: (2017)

Can glycopyrrolate come to the airway rescue in Covid-19 patients?
por: Garg, Heena
Publicado: (2020)

Glycopyrrolate and Post-Operative Urinary Retention: A Narrative Review
por: Low, Jason, et al.
Publicado: (2020)

Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer
por: Abd-Elaziz, Khalid, et al.
Publicado: (2020)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
por: Kerwin, Edward M., et al.
Publicado: (2019)

An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease
por: Pudi, Krishna, et al.
Publicado: (2019)

Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA
por: Lipworth, Brian J, et al.
Publicado: (2018)

Evaluation of efficacy and safety of glycopyrrolate - xylazine - propofol anesthesia in buffalo calves
por: Potliya, Sandeep, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2h3ums8nsq091771coa18njqiv